Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2001-04-13
2008-08-26
Belyavskyi, Michail A (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S141100, C424S155100, C424S156100
Reexamination Certificate
active
07416726
ABSTRACT:
The present invention is related to enhancing the function of anti-tumor antibodies by regulating FcγRIIB-mediated activity. In particular, disrupting SHIP activation by FcγRIIB enhances cytotoxicity elicited by a therapeutic antibody in vivo in a human. The invention further provides an antibody, e.g., an anti-tumor antibody, with a variant Fc region that results in binding of the antibody to FcγRIIB with reduced affinity. A variety of transgenic mouse models demonstrate that the inhibiting FcγRIIB molecule is a potent regulator of cytotoxicity in vivo.
REFERENCES:
patent: 4752601 (1988-06-01), Hahn
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5132405 (1992-07-01), Huston et al.
patent: 5348876 (1994-09-01), Michaelsen et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5476786 (1995-12-01), Huston
patent: 5554601 (1996-09-01), Simpkins et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5637687 (1997-06-01), Wiggins
patent: 5648260 (1997-07-01), Winter et al.
patent: 5677437 (1997-10-01), Teng et al.
patent: 5698449 (1997-12-01), Baumann et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5773231 (1998-06-01), Medford et al.
patent: 5780607 (1998-07-01), Goodnow, Jr. et al.
patent: 5783682 (1998-07-01), Cook et al.
patent: 5792844 (1998-08-01), Sanghvi et al.
patent: 5811234 (1998-09-01), Roninson et al.
patent: 5814500 (1998-09-01), Dietz
patent: 5834597 (1998-11-01), Tso et al.
patent: 5981229 (1999-11-01), Masure et al.
patent: 5985599 (1999-11-01), McKenzie et al.
patent: 6025198 (2000-02-01), Bennett et al.
patent: 6028053 (2000-02-01), van der Geer et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 2012311 (1990-09-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 88/07089 (1988-09-01), None
patent: WO 89/07142 (1989-08-01), None
patent: WO 92/05263 (1992-04-01), None
patent: WO 94/21807 (1994-09-01), None
patent: WO 94/29351 (1994-12-01), None
patent: WO 95/05468 (1995-02-01), None
patent: WO 95/18863 (1995-07-01), None
patent: WO 95/21931 (1995-08-01), None
patent: WO 95/28494 (1995-10-01), None
patent: WO 96/17823 (1996-06-01), None
patent: WO 96/25508 (1996-08-01), None
patent: WO 97/28267 (1997-08-01), None
patent: WO 97/44362 (1997-11-01), None
patent: WO 98/05787 (1998-02-01), None
patent: WO 98/23289 (1998-06-01), None
patent: WO 98/52975 (1998-11-01), None
patent: WO 99/01157 (1999-01-01), None
patent: WO 99/01158 (1999-01-01), None
patent: WO 99/01175 (1999-01-01), None
patent: WO 99/43713 (1999-09-01), None
patent: WO 99/51642 (1999-10-01), None
patent: WO 99/58572 (1999-11-01), None
patent: WO 00/09560 (2000-02-01), None
patent: WO 00/15214 (2000-03-01), None
Colman et al., Research in Immunology (145(1):33-36, 1994.
Abaza et al., Journal of Protein Chemistry (11(5):433-444, 1992.
Lederman et al Molecular Immunology (28:1171-1181, 1991.
Li et al PNAS 77:3211-3214, 1980.
Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al., (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495.
Pearse et al., Immunol., 1999, vol. 10, pp. 753-760.
Gupta, N., et al., “Negative signaling pathways of the killer cell inhibitory receptor and FcγIIb1 require distinct phosphatases,”J. Experimental Medicine, 1997, 186(3), 473-478.
Baselga, J., et al., “Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2
euoverexpressing human breast cancer xenografts,”Cancer Res., Jul. 1, 1998, 58, 2825-2831.
Bird, R.E., et al., “Single-chain antigen-binding proteins,”Science, Oct. 21, 1988, 242, 423-426.
Boder, E.T., et al., “Yeast surface display for screening combinatorial polypeptide libraries,”Nat. Biotechnol., Jun. 1997, 15, 553-557.
Bolland, S., et al., “SHIP modulates immune receptor responses by regulating membrane association of Btk,”Immunity, Apr. 1998, 8, 509-516.
Brooks, D.G., et al., “Structure and expression of human IgG FcRII(CD32) functional heterogeneity is encoded by the alternatively spliced products of multiple genes,”J. Exp. Med., Oct. 1989, 170, 1369-1385.
Buchwald, H., et al., “Long-term, continuous intravenous heparin administration by an implantable infusion pump in the ambulatory patients with recurrent venous thrombosis,”Surgery, Oct. 1980, 88(4), 507-516.
Burton, D.R., “Immunoglobulin G: functional sites,”Mol. Immunol., 1985, 22(3), 161-206.
Capel, P.J.A., et al., “Heterogeneity of human IgG Fc receptors,”Immunomethods, 1994, 4, 25-34.
Carter, P., et al., “Humanization of an anti-p185HER2antibody for human cancer therapy,”Proc. Natl. Acad. Sci. USA, May 1992, 89, 4285-4289.
Clackson, T., et al., “Making antibody fragments using phage display libraries,”Nature, Aug. 15, 1991, 352, 624-628.
Cochet, O., et al., “Intracellular expression of an antibody fragment-neutralizing p21 Ras promotes tumor regression,”Cancer Res.,Mar. 15, 1998, 58, 1170-1176.
Cox, A.L., et al., “Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines,”Science, Apr. 29, 1994, 264, 716-719.
Curiel, D.T., et al., “High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes,”Hum. Gene Ther., 1992, 3, 147-154.
Curiel, D.T., “Targeted tumor cytotoxicity mediated by intracellular single-chain anti-oncogene antibodies,” Gene Therapy Program,Advances in Pharmacology, 1997, 40, 51-84.
Daëron, M., “Fc receptor biology,”Annu. Rev. Immunol., 1997, 15, 203-234.
Damen, “The 145-kDa protein induced to associate with She by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase,”Proc. Natl. Acad. Sci. USA, 1996, 93, 1681693.
de Haas, M., et al., “Fcγ receptors of phagocytes,”J. Lab. Clin. Med., 1995, 126, 330-341.
Deisenhofer, J., “Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A fromStaphylococcus aureusat 2.9- and 2.8-Å resolution,”Am. Chem. Soc., Apr. 28, 1981, 20(9), 2361-2370.
During, M.J., et al., “Controlled release of dopamine from a polymeric brain implant: in vivo characterization,”Ann. Neurol., 1989, 25, 351-356.
Ellman, J., et al., “Biosynthetic method for introducing unnatural amino acids site-specifically into proteins,”Meth. In Enzym., 1991, 202, 301-336.
Felgner, P.L., et al., “Cationic liposome-mediated transfection,”Nature, Jan. 26, 1989, 337, 387-388.
Felgner, P.L., et al., “Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure,”Proc. Natl. Acad. Sci. USA, Nov. 1987, 84, 7413-7417.
Goodson, J.M., inMedical Applications of Controlled Release, 1984, vol. 2, 115-138.
Han, D.C., et al., “Therapy with antisense TGF-β1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice,”Am. J. Physiol. Renal Physiol., 2000, 278, F628-F634.
Hanna, A.K., et al., “Adenoviral-mediated expression of antisense RNA to basic fibroblast growth factor reduces tangential stress in arterialized vein grafts,”J. Vasc. Surg., 2000, 31, 770-780.
Howard, M.A., et al., “Intracerebral drug delivery in rats with lesion-induced memory deficits,”J. Neurosurg., 1989, 71, 105-112.
Huse, W.D., et al., “Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambada,”Science, Dec. 8, 1989, 246, 1275-1281.
Huston, J.S., et al., Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli, Proc. Natl. Acad. Sci. USA, Aug. 1988, 85, 58
Belyavskyi Michail A
Pepper Hamilton LLP
The Rockefeller University
LandOfFree
Enhancement of antibody-mediated immune responses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhancement of antibody-mediated immune responses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancement of antibody-mediated immune responses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4019106